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Abstract
Objective—This study examines whether the psychological traits of hopelessness and depressive
symptoms are related to endothelial dysfunction.
Methods—Data come from a subsample of 434 respondents in the 2001–2003 Chicago
Community Adult Health Study (CCAHS), a population-based survey designed to study the
impact of psychological attributes, neighborhood environment, and socio-economic circumstances
on adults age 18 and over. Circulating biomarkers of endothelial dysfunction including e-selectin,
p-selectin and s-ICAM1 were obtained from serum samples. Hopelessness was measured by
responses to two questions and depressive symptoms were measured by an 11-item version of the
CES-D. Multivariate regression models tested whether continuous levels of the biomarkers
(natural log transformed) were associated with levels of hopelessness and depressive symptoms
separately and concurrently.
Results—In age- and sex-adjusted models, hopelessness showed significant positive linear
associations with s-ICAM1. In contrast, there was no significant linear association between
hopelessness and e-selectin and p-selectin. Adjustment for clinical risk factors including systolic
pressure, chronic health conditions, smoking, and body mass index did not substantively alter
these associations. Results from similar models for depressive symptoms did not reveal any
association with the three biomarkers of endothelial dysfunction. The associations between
hopelessness and e-selectin and s-ICAM1 were robust to the inclusion of adjustments for
depressive symptoms.
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Conclusions—Negative psychosocial traits may influence cardiovascular outcomes partially
through their impact on the early stages of atherosclerosis, and specific psychosocial traits such as
hopelessness may play a more direct role in this process than overall depressive symptoms.
Introduction
Previous work has shown that psychosocial factors including hopelessness and depression
predict hypertension incidence, atherosclerotic progression, ischemic heart disease and acute
myocardial infarction (1–5). However, little is known about whether these psychosocial
factors also predict sub-clinical measures of endothelial dysfunction, an early precursor of
atherosclerosis. Understanding the pathophysiological mechanisms linking psychosocial
factors to cardiovascular disease is an important step in continued cardiovascular disease
(CVD) prevention efforts.
Endothelial dysfunction reflects a vascular phenotype prone to atherogenesis, serving as an
important predictor of cardiovascular events (6). Dysfunction of the endothelium typically
leads to immunological alterations including activation, adhesion, and aggregation of
platelets to areas of damage. Attachment of monocytes and lymphocytes to endothelial cells
is mediated by cellular adhesion molecules (CAMS), comprised of the selectin family (e-
selectin, p-selectin, and l-selectin) and the immunoglobulin group, including intercellular
adhesion molecule-1 (ICAM-1) (7, 8). Selectins are involved in the first step of leukocyte
adhesion at sites of inflammation or injury, while the intercellular adhesion molecule
mediates tight attachment of leukocytes and platelets to the endothelium (9). Levels of
soluble adhesion molecules reflect this process of inflammation of the vessel wall and have
been found to predict cardiovascular events in healthy populations (10–12).
A sense of hopelessness is characterized by a sense of futility and negative expectations
about the future and one’s personal goals. Hopelessness seems to lead to more negative
evaluations of new situations and less effective coping strategies (10). While hopelessness is
often a major symptom of depression, it may play a distinct and larger role in the
development of cardiovascular disease risk (2). Negative emotions such as hopelessness
may influence the progression of atherosclerosis through chronic stimulation of the
sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenocortical (HPA)
axis (11–14), which can injure the intima and vascular endothelial cells (15–17). Thus far,
little work has directly tested associations of hopelessness and inflammatory markers, with
one study finding no relationship in a subsample of the Whitehall II cohort (18). In another
study, plasma fibrinogen was found to be a moderate-strength mediator of the association
between hopelessness and progression of carotid atherosclerosis in Finnish men (19).
Nonetheless, numerous studies point to a relationship between psychosocial stress, negative
emotions, and increases in systemic inflammatory markers including C-reactive protein
(CRP), Interleukin-6 (Il-6), and tumor necrosis factor-α (TNF-α) (20–22). Since adhesion
molecules are thought to express on the endothelial membrane partly in response to several
inflammatory cytokines (23), we hypothesized that hopelessness will be associated with
circulating levels of these adhesion molecules.
Depression is characterized by a depressed mood, loss of interest or pleasure, feelings of
guilt or low-self work, disturbed sleep or appetite, and low energy. Several pathways have
been proposed to explain observed links between depression and CVD. Depression may be
associated with unhealthy lifestyles such as poor diet and lack of exercise, and non-
adherence to treatment regimens. Depression has been associated with higher levels of CRP,
IL-6, and tumor necrosis factor-α and increased monocyte expression of pro-inflammatory
cytokines and chemokines, and thus may foster inflammation that contributes to CVD (24),
although some studies have found no association of depression with inflammatory markers
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(25, 26). With regards to endothelial function, depression has been found to be associated
with impaired flow-mediated dilatation of the brachial artery (4). Depression may act as a
chronic stressor that contributes to endothelial dysfunction through abnormalities in cellular
adhesion, migration, and proliferation (4). Depression has previously been linked to higher
levels of ICAM-1, e-selectin, and monocytechemoattractant protein-1 in a clinical case-
controlled study (27). Given the existing evidence on depression and inflammatory
pathways, we expected that depression will be associated with markers of endothelial
dysfunction in our sample.
To the best of our knowledge, no previous study has examined the effect of hopelessness on
markers of sub-clinical endothelial dysfunction. One previous study examined the link
between depression and e-selectin in a clinical sample (27), but to our knowledge, the
association between depression and a broader set of endothelial markers in a population-
based sample has not been characterized. The objective of this study was to examine
whether hopelessness and depression are related to endothelial dysfunction, as measured by
serum values of three markers of endothelial function: e-selectin and p-selectin, and soluble
intercellular adhesion molecule-1 (s-ICAM1).
METHODS
Sample Population
Data for this study come from the first wave of the Chicago Community Adult Health Study
(CCAHS), a population-based survey designed to study the impact of psychological
attributes, neighborhood environment, and socio-economic circumstances on adults aged 18
and over, conducted from 2001–2003. Sociodemographic and psychosocial data were
collected on the full CCAHS sample (N=3105) during the interview portion of the study.
Full details of the CCAHS have been reported elsewhere (28). All subjects gave informed
consent for both the interviews and serum collection, and these studies were approved by the
University of Michigan School of Public Health Institutional Review Board. Blood samples
were drawn by certified phlebotomists for a random subsample of 661 respondents from 80
neighborhoods, frozen at least −20C by Quest Laboratories Chicago, and shipped to the
Central Ligand Assay Satellite Services (CLASS) Laboratory in Ann Arbor, MI, where they
were stored at -70 C until the time of analysis. All three biomarkers were assayed with
ELISA Kits (R&D systems, Minneapolis, MN). We excluded individuals who reported ever
having a heart attack or had missing values on any of the biomarkers or independent
variables. The resulting final sample size for analyses consisted of 434 observations.
Measures
Key Independent Variables: Hopelessness was measured with 2 items from the Kuopio
Ischemic Heart Disease (KIHD) study that capture negative expectations about oneself and
the future: 1.) I feel it is impossible for me to reach the goals I would like to strive for. 2.)
The future seems hopeless to me and I can’t believe that things are changing for the better.
These two questions have been used in previous studies that examined the relationship
between hopelessness and cardiovascular disease (1, 2, 29). For each question, respondents
answered on a scale of 1 to 4 whether they agreed strongly with the statement, agreed
somewhat, disagreed somewhat, or disagreed strongly. Each response was then reverse
coded and summed. We used the sum score to reflect a continuous measure of hopelessness.
In addition, in order to capture possible nonlinear effects, we also examined a categorical
classification of hopelessness level specified by the following delineation. The summed
scores (range 2 to 8) were divided into three categories (low hopelessness (score=2),
medium hopelessness (3 ≥ score ≤ 5), high hopelessness (6 ≥ score ≤ 8)). A score of 2
reflected consistent strong disagreement with each statement, scores from 3 to 5 indicated a
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more mixed response, and scores from 6 to 8 reflected general agreement with the
statements. While not identical due to differences in scale, we base our grouping to reflect
the degree of disagreement with the hopelessness measures that have been employed in
previous studies (1, 2).
Depressive symptoms were measured by a shortened version of the Center for
Epidemiological Studies-Depression Scale CES-D, which was developed for use in the Iowa
cohort of the Established Populations for Epidemiologic Study of the Elderly (EPESE)
survey. This shortened version of the scale employs 11 of the 20 items used in the long form
of the CES-D (The 11 question items are included in the Appendix) (30, 31). For each
question, respondents were asked to answer on a scale of 1 to 4 the frequency in which they
experienced certain feelings during the past week. The frequency ranged from 1) never, 2)
hardly ever, 3) some of the time, and 4) most of the time. Similar to our strategy with the
hopelessness measure, we used both a continuous score and a categorical specification to
examine possible threshold effects. The continuous score reflected the sum of the scores
from the 11 items. Two questions that had asked about positive feelings (i.e., happiness,
enjoyment of life) were first reverse coded before being summed. For the categorical
specification, we first transformed the score distribution to reflect the distribution of the 20
item scale in a nationally represented sample, using the procedure recommended by Kohout
et al. (30). Briefly, we standardized male and female scores separately through a T score
transformation which shifted the mean and standard deviation to those from the NHANES-I
(mean=7.1, sd=7.2 for men and mean=10.0, sd = 9.1 for women). We then created a binary
indicator based on the standard cutoff score of 16, reflecting high depressive symptoms (32).
Outcome—Outcome measures include three markers of endothelial function: p-selectin
(ng/mL), e-selectin (ng/mL), s-ICAM1 (ng/mL). Due to their skewed distributions, each
marker was natural log transformed for all analyses.
Covariates—We adjusted for a series of individual sociodemographic and health
characteristics, including: gender, age (continuous), inflammatory disease (binary indicator
of whether the respondent has ever been diagnosed with asthma, arthritis, ulcer, or
emphysema), cardiovascular disease (binary indicator of whether the respondent has ever
been diagnosed with heart condition, stroke, peripheral artery disease, or diabetes), systolic
BP level (continuous), BMI category (normal (BMI<25), overweight (25 ≥ BMI<30), obese
(BMI ≥ 30)) and smoking status (never smoked, past smoker, current smoker).
Statistical Analysis
We estimated a series of multivariable regression models examining the relationship
between each marker of endothelial dysfunction and levels of hopelessness and depression,
separately and then concurrently. In primary analyses, hopelessness and depressive
symptoms were modeled continuously. To capture possible non-linear effects, as well as to
allow meaningful interpretations of differences in outcomes between high and low levels of
psychosocial risk, the same models were then repeated with levels of hopelessness and
depressive symptoms specified categorically, as described above.
We first estimated a set of models that adjusted for only age and gender (Models 1). Because
existing health conditions may lead to hopelessness or depression, we then adjusted for
systolic blood pressure level, self-reported inflammatory conditions, and self-reported
cardiovascular conditions (Models 2). Finally, since deleterious health behaviors might
confound or be a result of hopelessness or depression and contribute to endothelial
dysfunction, we included BMI level and smoking status in the models as potential
confounders/mediators (Models 3). This sequence of models was first conducted for
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hopelessness and depressive symptoms separately and then, because hopelessness and
depressive symptoms are known to be correlated, we estimated the same set of models with
both hopelessness and depression specified concurrently to assess their independent
influences.
Further models that included LDL cholesterol level and income were estimated as sensitivity
analyses to test the robustness of our results, but were not included in the primary analyses
due to the amount of missing data and subsequent loss of power.
Results
Simple cross tabulations for hopelessness and depressive symptoms with various sample
characteristics were first conducted. Selected sample descriptives by hopelessness levels are
presented in Table 1. A higher proportion of individuals indicating either low or high
hopelessness was female, and the average age increased with levels of hopelessness.
Moreover, a higher proportion of those with high hopelessness reported having an existing
health conditions (i.e., cardiovascular condition, inflammatory condition), had higher
systolic blood pressure, were obese, and currently smoked.
The pattern found for levels of depressive symptoms was similar, with some notable
exceptions (Table 2). Similar to hopelessness, a higher proportion of those with high levels
of depressive symptoms was female and the average age was higher among the high
depressive symptoms group. A considerably higher proportion of those with high levels of
depressive symptoms reported having a cardiovascular or inflammatory condition and
currently smoked. However, levels of systolic blood pressure and rates of obesity were
similar for the low and high depressive symptoms groups.
Simple correlation analyses revealed that the continuous measures of hopelessness were
significantly correlated with e-selectin (r=0.13, p-value=0.001) and s-ICAM1 (r=0.15, p-
value=0.002) but not p-selectin (r=0.00, p-value=0.96). In contrast, depressive symptoms
were not significantly correlated with any of the biomarkers (r=0.04, p-value=0.44 with e-
selectin; r=−0.01, p-value=0.88 with p-selectin; r=0.05, p-value=0.28 with s-ICAM1).
Results from regression models indicated that hopelessness, specified continuously, was
significantly associated with only one of the three endothelial markers (Table 3). The age-
and gender-adjusted models suggested a strong positive association with s-ICAM1 in which
each additional point of hopelessness was associated with a 3.36 percent increase in levels of
s-ICAM1. The magnitude of the association was consistently reduced with each set of
additional adjustments but remained significant upon the addition of controls for health
conditions and health behaviors. No significant association was found for e-selectin or p-
selectin when hopelessness was measured continuously.
Analyses specifying categorical measures of hopelessness suggested a stepwise relationship
between hopelessness and two of the endothelial dysfunction markers. Relative to the lowest
level, respondents in the highest level of hopelessness had over 18% higher levels of e-
selectin and s-ICAM1 – though the association for e-selectin was only marginally
significant. No association was found between hopelessness levels and p-selectin.
Adjustments for health conditions (i.e., CVD conditions, non-inflammatory conditions,
systolic blood pressure) did not alter the associations (Models 2; Table 3), nor did the
inclusion of BMI and smoking status in the final models (Models 3; Table 3). The
association between high hopelessness and e-selectin became statistically significant with
the full set of adjustments, and the association between a medium level of hopelessness and
e-selectin became marginally statistically significant with the inclusion of the additional set
of controls.
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The results for age- and sex-adjusted models for depressive symptoms did not support any
association with endothelial dysfunction. Both the continuous and categorical specifications
of depressive symptoms yielded nominal (i.e., point estimates were close to zero)
associations with the three biomarkers and none were significant. The inclusion of additional
adjustments did not significantly alter these findings (Table 4).
Regression models with hopelessness and depressive symptoms included together suggested
that not only was the association of hopelessness and endothelial dysfunction independent of
depressive symptoms, it is strengthened upon adjustment. In the continuous models, the
magnitude of the point estimates for hopelessness increased for all three biomarkers,
compared to comparable models without adjusting for depressive symptoms (Table 5). A
single point increase in the hopelessness score was associated with an increase of between 3
to 4 percent for e-selectin and s-ICAM1. However, consistent with models not adjusting for
depressive symptoms, hopelessness was found to be significantly associated only with s-
ICAM1. However, in the categorical models, high levels of hopelessness were found to be
significantly associated with e-selectin (compared to marginal significance in previous
models without controlling for depressive symptoms) across all three model specifications
(Table 6). Medium levels of hopelessness were marginally associated with e-selectin. High
levels of hopelessness remained significantly associated with s-ICAM1 upon the inclusion
of depressive symptoms. As before, no association was found between hopelessness and p-
selectin in the categorical models. Depressive symptoms remained unassociated with all
three biomarkers in both the continuous and categorical models.
Discussion
This study identified associations between hopelessness and two out of three adhesion
molecules thought to be early markers of endothelial dysfunction, a precursor to
atherosclerosis. Significant associations of hopelessness with s-ICAM1 were found, net of
an extensive list of controls for other risk factors for atherosclerosis including smoking,
obesity, hypertension, and existing chronic conditions in both the continuous and categorical
models. A weaker link was found between hopelessness and e-selectin where high
hopelessness was revealed to be significantly associated with e-selectin only after
controlling for gender, health conditions, and health behaviors. Hopelessness was not found
to be linearly associated with e-selectin. In contrast, we found no evidence to support a link
between hopelessness and p-selectin. The differing results across the three biomarkers were
not surprising, given the range of correlation strengths; p-selectin and s-ICAM1 were not
correlated (r=0.027, p-value=0.569), p-selectin and e-selectin had a low correlation
(r=0.172, p-value<0.001), and e-selectin and s-ICAM1 had the strongest correlation
(r=0.314, p-value<0.001).
The lack of an association between hopelessness and p-selectin may suggest distinct
pathways of influence; in contrast to s-ICAM1 and e-selectin which are activated by
inflammatory cytokines, p-selectin has been considered most importantly a marker of
platelet activation stimulated by thrombin and adenosine diphosphate (ADP) (33, 34). In
addition, biological determinants of p-selectin differ from those of e-selectin. Ponthieux et al
found e-selectin to be positively associated with glucose and TNF-alpha, while p-selectin
was negatively associated with these markers (7). Moreover, there are gender differences in
p-selectin, but not e-selectin (7). Finally, e-selectin increases with BMI, while p-selectin
does not show such an association (7).
We found no evidence that depressive symptoms were associated with any of the three
endothelial markers. These results are in contrast to the one existing study that examined the
relationship between depression and adhesion molecules. Rajagopalan et al. found
depression to be positively associated with s-ICAM and e-selectin (27). This study was a
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case-control clinical study of young adult patients with Major Depressive Disorder rather
than a population-based study of depressive symptoms, which may account for the different
findings. Additional models with a higher CES-D cutoff point of 20, suggestive of higher
degree of depression, were estimated as sensitivity analyses; no association with endothelial
biomarkers was found in any of these models. Recent work identified a stronger relationship
between somatic items (such as poor appetite and fatigue) of the 20-item CESD scale and
future risk of cardiovascular events in women with existing CVD (35) compared to
cognitive/affective symptoms. Since somatic items comprised only 2 of our 11 CESD items,
this may help explain our negative findings for depression.
Sensitivity analyses were conducted to assess the robustness of our findings for
hopelessness. Given cholesterol is a known risk factor for endothelial dysfunction, we tested
the robustness of the associations to the inclusion of LDL cholesterol level, with very similar
results. Further, because socioeconomic conditions may be correlated with hopelessness, we
estimated models that included the respondent’s income as a possible confounder or
mediator (results not shown); the significant associations remained for s-ICAM1 even after
adjustment for this socioeconomic measure. However, the associations for e-selectin were
attenuated to non-significance, suggesting that income confounded or mediated the
relationship between hopelessness and e-selectin. In summary, we found hopelessness to be
consistently associated with s-ICAM1, independent of health measures and behaviors,
including depressive symptoms. A weaker association was found for e-selectin and only
presented when comparing high levels to low levels of hopelessness. No association
between hopelessness and p-selectin was found.
The results for hopelessness suggest that negative psychosocial traits may influence
cardiovascular outcomes partially through their impact on early stages of atherosclerosis.
Our findings are consistent with work that found plasma fibrinogen to be a moderate-
strength mediator of the association between hopelessness and progression of carotid
atherosclerosis in Finnish men (19). Fibrinogen is an acute phase reactant and marker of
inflammation that strongly affects platelet aggregation, and may also be an indication of
injury to vascular endothelial cells (36). Over-expression of the cell adhesion molecules
examined in this study may in part represent a response to inflammatory stimuli (37). There
is very little existing literature on the relationship of hopelessness to inflammatory markers
(with one exception (18)); future work should confirm whether inflammation mediates the
relationship between hopelessness and endothelial function, or whether other pathways are
more salient.
The distinct results for hopelessness and depression suggest that hopelessness may reflect a
unique component of depression that may be more relevant to cardiovascular function than
measures of depressive symptoms. It is possible that hopelessness reflects a long-term
consequence of high levels of depressive symptoms, and thus reflects a more severe state.
Indeed, the correlation between our measures of hopelessness and depressive symptoms was
only 0.43 (p-value<0.001). The relatively low correlation between these two measures
supports the notion that hopelessness and depressive symptoms do not go hand in hand and
that hopelessness may be a sufficient but not necessary component of depression.
Specifically, hopelessness may be indicative of high depressive symptoms while the reverse
may not be true.
The relative strength of the associations found for hopelessness versus depressive symptoms
has also been found by several other studies examining cardiovascular disease (1–3, 29, 38).
For example, studies have found hopelessness to be associated with incident myocardial
infarction and cardiovascular mortality (1) and faster progression of carotid atherosclerosis
over a 4 year follow-up (3). These associations were not substantially altered after
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controlling for depressive symptoms. In studies that examined hopelessness and depressive
symptoms separately, hopelessness was found to be a stronger predictor of incident fatal and
nonfatal ischemic heart disease in both men and women (38).
The puzzle of how and why hopelessness is uniquely associated with cardiovascular disease,
independent of depressive symptoms, is further complicated by consistent findings that
traditional risk factors do not mediate the association between hopelessness and
cardiovascular disease (1–3). Our findings were consistent with this pattern, with no
confounding or mediating influence of obesity, hypertension, or smoking in our observed
relationship between hopelessness and adhesion molecules. Since these risk factors were
measured at one point in time and likely measured with error, our models may not reflect the
full influence of these factors. Additional risk factors not measured here may be important
mechanisms, such as cortisol secretion, inflammatory cytokines, dietary-influenced factors
such as homocysteine, or shared genetic factors (14).
Nonetheless, it is becoming increasingly evident that hopelessness is an important and
unique contributor to cardiovascular disease. We hypothesize that hopelessness, compared
to depressive symptoms, reflects a more chronic and permanent attribute that may
progressively affect physiological pathways over time. However, our cross-sectional study
does not allow us to test this hypothesis. Future studies using longitudinal data that has
information on the dynamics (e.g., onset, duration) of respondents’ psychosocial states may
help to reveal why hopelessness is such a strong predictor of cardiovascular related health
outcomes. Moreover, longitudinal analyses can begin to examine to what extent income
mediates or confounds the relationship with e-selectin. While a strength of our study is the
use of a population rather than clinical sample, our sample is limited to a discrete geographic
area which may be not generalizable to the U.S. population. In addition, the sample sizes of
respondents with high hopelessness and depression are relatively small which may be
problematic for detecting a given effect size.
Despite this study’s weaknesses, our findings both support and contribute to previous studies
examining the relationship between psychosocial factors and cardiovascular disease. While
previous papers have identified associations between hopelessness and later stages of
atherosclerosis and its progression as measured by intima-media thickening (IMT) (3), this
is the first study to examine the association of hopelessness with the cellular adhesion
molecules s-ICAM1, e-selectin, and p-selectin. Our results suggest that hopelessness may be
a risk factor in early identification of those with higher risk for cardiovascular related health
problems. Associations were strongest for s-ICAM1, weaker for e-selectin, and absent for p-
selectin. Future studies should work to replicate these findings, investigate why the
association between hopelessness and endothelial markers vary across different cellular
adhesion molecules, and identify additional mechanisms linking hopelessness to endothelial
dysfunction.
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